Evidence map›Paper›PMID 37268724›Full record

Trial reportNature medicine2023

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.

Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich and 23 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02886585 (Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02886585 phase2active not recruitingnot on this map

Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies

TypeinterventionalSponsorMassachusetts General HospitalRan2016 to 2028Enrolled101ConditionsBrain MetastasesArmsPembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 3 institutions in 1 country.

Priscilla K Brastianos *Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-4470-8425
Albert E Kim *Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Anita Giobbie-HurderDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2496-7737
Eudocia Q LeeDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nancy U LinDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Beth OvermoyerDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4438-7000
Patrick Y WenDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lakshmi NayakDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Justine V CohenAbramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Jorg DietrichMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
April EichlerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Rebecca S HeistMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ian KropYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Donald LawrenceMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Jennifer LigibelDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Sara TolaneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671
Erica MayerDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5430-8957
Eric WinerYale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Brittany BentMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Magali A de SauvageMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Nazanin IjadMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Juliana M LarsonMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Braxton MarionMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Sally NasonDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Naina MurthyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Sherry RatcliffMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Elizabeth J SummersMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Maura MaharMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Helen A ShihMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Kevin OhMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Daniel P CahillMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Elizabeth R GerstnerMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ryan J SullivanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5344-6645
Harvard University · USYale Cancer Center · USUniversity of Pennsylvania · US

Funding

Identification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, CARTER, SCOTT · 2018 to 2022
$3.5M
Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BRASTIANOS, PRISCILLA KALIOPI, GERSTNER, ELIZABETH · 2020 to 2024
$3.4M
Evaluation of metastatic brain tumor heterogeneity and physiological response to immunotherapy using advanced MRIR01CA211238 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GERSTNER, ELIZABETH · 2017 to 2019
$409k
NCI NIH HHS R01 CA211238NCI NIH HHS R01 CA227156NCI NIH HHS R01 CA244975
6 · The paper itself

Abstract

Brain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies. The primary endpoint was the proportion of patients achieving intracranial benefit, defined by complete response, partial response or stable disease. The primary endpoint was met with an intracranial benefit rate of 42.1% (90% confidence interval (CI): 31-54%). The median overall survival, a secondary endpoint, was 8.0 months (90% CI: 5.5-8.7 months) across both cohorts, 6.5 months (90% CI: 4.5-18.7 months) for cohort A and 8.1 months (90% CI: 5.3-9.6 months) for cohort B. Seven patients (12.3%), encompassing breast, melanoma and sarcoma histologies, had overall survival greater than 2 years. Thirty patients (52%; 90% CI: 41-64%) had one or more grade-3 or higher adverse events that were at least possibly treatment related. Two patients had grade-4 adverse events (cerebral edema) that were deemed at least possibly treatment related. These results suggest that programmed cell death protein 1 blockade may benefit a select group of patients with BMs, and support further studies to identify biomarkers and mechanisms of resistance. ClinicalTrials.gov identifier: NCT02886585.

Indexed as

Brain NeoplasmsMelanomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, Humanizedpembrolizumab

Identifiers

PMID37268724
PMCPMC10644912
OpenAlexW4379162563

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.